Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
An Open-label Phase 1b/2 Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy
Sponsor: Wave Life Sciences Ltd.
Listed as NCT04906460, this PHASE1/PHASE2 trial focuses on Duchenne Muscular Dystrophy and remains actively recruiting participants. Sponsored by Wave Life Sciences Ltd., it has been updated 13 times since 2021, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
13 versions recorded-
Jan 2026 — Present [monthly]
Recruiting PHASE1/PHASE2
-
Nov 2025 — Jan 2026 [monthly]
Recruiting PHASE1/PHASE2
Status: Active Not Recruiting → Recruiting
-
Oct 2025 — Nov 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jun 2025 — Oct 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Mar 2025 — Jun 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
▶ Show 8 earlier versions
-
Sep 2024 — Mar 2025 [monthly]
Active Not Recruiting PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Mar 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2022 — Mar 2024 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2022 — Sep 2022 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2021 — Jun 2022 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2021 — Nov 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Wave Life Sciences Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .